Expansion of allogeneic NK cells with efficient antibody-dependent cell cytotoxicity against multiple tumors by Sanchez-Martinez, D. et al.
Theranostics 2018, Vol. 8, Issue 14 
 
 
http://www.thno.org 
3856 
Theranostics 
2018; 8(14): 3856-3869. doi: 10.7150/thno.25149 
Research Paper 
Expansion of allogeneic NK cells with efficient 
antibody-dependent cell cytotoxicity against multiple 
tumors 
Diego Sanchez-Martinez1,#, Nerea Allende-Vega1,2,#, Stefania Orecchioni3, Giovanna Talarico3, Amelie 
Cornillon1, Dang-Nghiem Vo1, Celine Rene1, Zhao-Yang Lu1, Ewelina Krzywinska1, Alberto Anel4, Eva M. 
Galvez5, Julian Pardo4, Bruno Robert6, Pierre Martineau6, Yosr Hicheri7, Francesco Bertolini3, Guillaume 
Cartron7 and Martin Villalba1,2, 
 IRMB, Univ Montpellier, INSERM, CHU Montpellier, Montpellier, France. 1.
 IRMB, CHU Montpellier, France. 2.
 Laboratory of Hematology-Oncology, European Institute of Oncology, Milan, Italy. 3.
 University of Zaragoza/Institute of Health Research of Aragón (IIS-Aragón), Spain.  4.
 Instituto de Carboquimica, Consejo Superior de Investigaciones Científicas (CSIC). 5.
 IRCM, INSERM U1194, Univ Montpellier, France. 6.
 Département d'Hématologie Clinique, CHU Montpellier, Univ Montpellier, France. 7.
# These two authors have equally contributed to this manuscript  
 Corresponding author: martin.villalba@inserm.fr (MV) 
© Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license 
(https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions. 
Received: 2018.01.25; Accepted: 2018.04.26; Published: 2018.06.14 
Abstract 
Monoclonal antibodies (mAbs) have significantly improved the treatment of certain cancers. 
However, in general mAbs alone have limited therapeutic activity. One of their main mechanisms of 
action is to induce antibody-dependent cell-mediated cytotoxicity (ADCC), which is mediated by 
natural killer (NK) cells. Unfortunately, most cancer patients have severe immune dysfunctions 
affecting NK activity. This can be circumvented by the injection of allogeneic, expanded NK cells, 
which is safe. Nevertheless, despite their strong cytolytic potential against different tumors, clinical 
results have been poor.  
Methods: We combined allogeneic NK cells and mAbs to improve cancer treatment. We 
generated expanded NK cells (e-NK) with strong in vitro and in vivo ADCC responses against 
different tumors and using different therapeutic mAbs, namely rituximab, obinutuzumab, 
daratumumab, cetuximab and trastuzumab.  
Results: Remarkably, e-NK cells can be stored frozen and, after thawing, armed with mAbs. They 
mediate ADCC through degranulation-dependent and -independent mechanisms. Furthermore, 
they overcome certain anti-apoptotic mechanisms found in leukemic cells.  
Conclusion: We have established a new protocol for activation/expansion of NK cells with high 
ADCC activity. The use of mAbs in combination with e-NK cells could potentially improve cancer 
treatment. 
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Introduction 
Recent progress in cancer treatment is primarily 
related to the development of novel targeted therapies 
[1]. These require the identification of suitable targets 
that are mainly expressed by the tumor cell 
population and/or playing a critical role in neoplastic 
cell growth. Therapeutic monoclonal antibodies 
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(mAbs) particularly illustrate this concept. Indeed, 
rituximab (RTX), an IgG1 mAb directed against CD20 
antigen, has now become the treatment of choice for 
most B-cell chronic lymphocytic leukemias (B-CLL) 
and B-cell non-Hodgkin’s lymphomas (B-NHL). The 
combination of RTX with conventional chemotherapy 
has shown better efficacy in randomized clinical trials. 
Similar success has been found with other cytotoxic 
mAbs, such as trastuzumab in breast cancer or 
cetuximab in colorectal carcinoma and squamous cell 
carcinoma of the head and neck [2, 3]. Nevertheless, 
mAbs alone generally have modest clinical activity. 
For example, the anti-CD20 mAbs RTX and 
obinutuzumab (OBZ; previously GA101, Roche, 
Genentech), when used as monotherapy in patients 
with relapsed follicular lymphoma (FL), have only led 
to short progression-free survival (PFS) [4]. Thus, 
there is a need to optimize their use in combination 
therapy. 
RTX success is related to its capacity to induce 
Fc-antibody-dependent cell-mediated cytotoxicity 
(ADCC). One receptor for human IgG1 is FcγRIIIa 
(CD16a), which is expressed on natural killer (NK) 
cells and macrophages. The link between 
FcγRIIIa-158VF polymorphism and RTX clinical 
responses strongly suggests that ADCC is critical [5]. 
This polymorphism is located on the extra-cellular 
domain of FcγRIIIa, and amino-acid 158 is involved in 
the interaction with CH2 of human IgG1 [4]. Human 
IgG1 has a higher affinity for VV-NK cells compared 
to FF-NK cells [5]. Based on these observations, there 
has been an attempt to produce new anti-CD20 mAbs 
by either Fc mutations or by glycoengeenering that 
exhibit higher affinity for FcγRIIIa [4, 6]. Lowering the 
fucose content of the N-glycan is currently under 
clinical investigation in B-cell malignancies with the 
mAb OBZ, which shows stronger ADCC in vitro and 
in a lymphoma xenograft mouse model relative to 
RTX. It also demonstrated improved clinical activity 
for treating B-CLL and other B-cell malignancies [4]. 
OBZ is approved for first-line B-CLL in association 
with chlorambucil, and in combination with 
bendamustine for the treatment of patients with FL 
who relapse or are refractory to a RTX-containing 
regimen [4]. Initial results show that lenalidomide, 
which stimulates NK cell activity [7], activates NK 
cells in OBZ-treated patients[8]. 
NK cells mediate ADCC but also possess natural 
cytotoxicity, which is mediated by engagement of 
their natural cytotoxicity receptors (NCRs). These 
play a central role in triggering NK activation. In 
humans, NKp30, NKp46, and NKp80 are 
constitutively expressed on resting and activated NK 
cells [9]. The NK cell-activating receptor CD16 
mediates ADCC. Hematological cancer patients 
possess antitumor NK cells that are unable to control 
disease [10, 11]. Notably, blood-borne tumor cells use 
different mechanisms for immune escape [12, 13], e.g., 
by inducing NK cell dysfunction [7, 14]. This 
mechanism has also been observed in a variety of 
patients of solid tumors [3]. In addition, NK cell 
differentiation may be inhibited by the presence of 
tumor cells, e.g., acute myeloid leukemia (AML) cells 
infiltrating bone marrow [15, 16]. Therefore, the 
failure of mAbs in monotherapy could be related to 
impaired NK cell function. Hence, there is a clinical 
interest to reactivate or replace patient NK cells [17]. 
Clinical-grade production of allogeneic NK cells is 
efficient and NK cell-mediated therapy after 
hematopoietic stem cell transplantation (HSCT) seems 
safe [16, 18, 19]. Despite the strong cytolytic potential 
of expanded NK cells against different tumors, clinical 
results have been very limited [16, 18, 19]. 
The combination of allogeneic NK cells with 
mAb could improve cancer treatment by replacing the 
defective effector immune cells. In addition, mAbs 
would effectively guide these effectors to their tumor 
targets. Several groups have tried this combination 
with varying results that could be due to deficient 
CD16 expression or lack of proper activation of 
expanded NK [20-23]. In addition, these studies did 
not include a systematic evaluation of the effect of 
these cells in combination with several mAbs on 
different tumors, nor did they include primary tumor 
cells.  
The aim of this work was to generate allogeneic 
NK cells with strong ADCC response against different 
tumors and mediated by different therapeutic mAbs. 
In addition, NK cell production should be easily 
scaled up and developed with good manufacturing 
practices (GMP). We have produced umbilical cord 
blood (UCB)-derived NK cells because UCB are 
rapidly available, present low risk of viral 
transmission and have less strict requirements for 
HLA matching and lower risk of graft-versus-host 
disease (GvHD) [18]. For NK cell expansion we used 
Epstein–Barr virus (EBV)-transformed 
lymphoblastoid B cell lines as accessory cells, which 
induce a unique genetic reprogramming of NK cells 
[24]. This generates effectors that overcome the 
anti-apoptotic mechanism of leukemic cells [25] and 
that are able to eliminate tumor cells from patients 
with poor prognosis [26]. We show that NK cells 
obtained with our protocol are able to perform ADCC 
in vitro and in vivo. The ADCC response was induced 
by using different therapeutic antibodies and against 
multiple target cells. 
 Theranostics 2018, Vol. 8, Issue 14 
 
 
http://www.thno.org 
3858 
Methods 
Ethics statement 
Experimental procedures were conducted 
according to the European guidelines for animal 
welfare (2010/63/EU). Protocols were approved by 
the Animal Care and Use Committee “Languedoc- 
Roussillon” (approval number: CEEA-LR-12163). The 
use of human specimens for scientific purposes was 
approved by the French National Ethics Committee. 
All methods were carried out in accordance with the 
approved guidelines and regulations of this 
committee. Written informed consent was obtained 
from each patient prior to surgery. 
Chemicals 
The D1D2 peptide has been previously described 
[27]. IL-2 and IL-15 were obtained from Miltenyi 
Biotec. To produce deglycosylated cetuximab, a 
commercial cetuximab solution was treated overnight 
with PNGAseF (Promega) at 37 °C in 50 mM sodium 
bicarbonate buffer (pH 7.8) at 125 U/mg of 
cetuximab. Deglycosilated cetuximab was purified by 
gel filtration using a Sephadex 75 column in PBS, and 
sterilized by filtration. The AF 647 Goat F(AB')2 anti 
human IgG (H+L) min x (BOV, HRS, MS) was from 
Interchim. 
B-CLL patients 
Data and samples from patients were collected at 
the Clinical Hematology Department of the CHU 
Montpellier, France, after patients’ written consent 
and following French regulations. Patients were 
enrolled in two independent clinical programs 
approved by the “Comités de Protection des 
Personnes Sud Méditerranée I”: ref 1324 and 
HEMODIAG_2020 (ID-RCB: 2011-A00924-37). 
Samples were collected at diagnosis and kept by the 
CHU Montpellier [11, 28]. For analysis, peripheral 
blood mononuclear cells (PBMCs) were obtained by 
ficoll gradient and stored frozen in liquid nitrogen 
until use. The percentage of CD19+CD5+ cells was 
always higher than 90%. Other samples from 
hematological cancer patients were obtained from the 
same collections. 
Cell lines 
The (EBV)-transformed lymphoblastoid B cell 
line PLH, the hematopoietic cell lines HL60 and 
MV4-11 (acute myeloid leukemia), Daudi and Raji 
(Burkitt's lymphoma derived, CD20+), K562 
(erythroleukemia), MM.1S and U266 (multiple 
myeloma), MEC1 (B-chronic lymphocytic leukemia) 
and its variants MEC-1-BCL-XL and MEC-1-MCL-1 
were cultured in 10% FBS RPMI medium. The 
adherent cell lines Calu-1 (lung cancer), A549 (lung 
adenocarcinoma), SK-OV-3 (ovarian carcinoma) and 
SKBR3 (breast adenocarcinoma) were cultured in 10% 
FBS DMEM medium. 
PBMC and UCBMC purification 
UCBs were obtained from healthy donors from 
the CHU Montpellier. Prof. John de Vos is the 
responsible of the “Collection du Centre de Resources 
Biologiques du CHU de Montpellier” – 
http://www.chu-montpellier.fr/fr/plateformes 
(Identifiant BIOBANQUES - BB-0033-00031). PBMC 
and UCB mononuclear cells (UCBMC) were 
respectively collected from peripheral blood samples 
and UCB units using Histopaque -1077 (Sigma). 
Briefly, 13 mL Histopaque was added to 50 mL 
centrifugation tubes and 30 mL of 1/2 diluted blood 
in RPMI, (Invitrogen) was slowly added at the top. 
Tubes were centrifuged at 400 rcf for 30 min at 20 °C 
without brake. Mononuclear cells were collected from 
the interlayer white ring, washed in RPMI and 
suspended in RPMI medium supplemented with 10% 
FBS (Invitrogen). 
Isolation and activation of human NK cells 
Frozen UCBMCs were depleted of T cells by 
using EasySepTM CD3 Positive Selection Kit 
(STEMCELL technologies). Cells were cultured for 10 
to 20 days with γ-irradiated PLH cells at 1:1 NK 
cell:accessory cell ratio in the presence of IL-2 (100 
U/mL) and IL-15 (5 ng/mL), or with IL-2 alone (1000 
U/mL). PLH cells were added every four days and 
fresh cytokines every two days. At the end of the 
process, NK cell purity (CD56+/CD3-) was always 
higher than 90%. 
FACS analysis 
For phenotype analysis, cells were stained with 
7AAD (Beckman) to identify viable cells and 
antibodies against the surface markers CD25-FITC, 
CD45RO-FITC, CD69-PE, CD62L-PE, CD19-PE, 
CD3-PE, CD19-ECD, CD56-PECy7, CD56-APC, 
CD3-APC, CD45-APCAlexaFluor750, CD45RA-APC-
AlexaFluor750, CD16-PacificBlue, CD57-PacificBlue, 
CD45-KromeOrange, CD16-KromeOrange (Beck-
man), CD158b-FITC, CD158a-PE, CD107a-HV500 (BD 
Biosciences), CD158e-Vioblue (Miltenyi). 1×105–3×105 
cells were incubated for 20-30 min at 4 °C with 
different antibodies in PBS containing 2.5% FBS. Cells 
were then washed and suspended in 200-250 µL of the 
same media. Staining was analyzed on a Gallios flow 
cytometer (Beckman) using the Kaluza software. 
Alive lymphocytes were gated using FSC/SSC and 
7AAD staining. B lymphocytes (CD19+), T 
lymphocytes (CD3+CD56-) and NK cells 
(CD56+CD3-) were distinguished using, respectively, 
CD19, CD3 and CD56 antibodies. 
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NK cell-mediated cytotoxicity 
Fresh or frozen (stored in liquid nitrogen) NK 
cells were labeled with 3 µM of CellTracker™ Violet 
BMQC Dye (Life Technologies) and incubated 
overnight with target cells at different E:T ratios. 
Subsequently, phosphatidylserine (PS) translocation 
and membrane damage were analyzed in the violet 
fluorescence-negative target cell population by flow 
cytometry using Annexin V-FITC (Immunostep) and 
7AAD (BD Biosciencies) or propidium iodide (PI) as 
previously described [25, 29]. We consider all cells 
positive for annexin-V and/or PI (or 7-ADD) as dead 
(or dying).  
In ADCC experiments, we incubated target cells 
with the relevant antibodies (RTX and OBZ at 10 
µg/mL; daratumumab, cetixumab and trastuzumab 
at 5 µg/mL) for 30 min at 37 °C. To arm NK cells, we 
incubated them at the same concentration of 
antibodies before washing and incubation with target 
cells. EGTA was used at 1 mM to block the granular 
exocytosis pathway and MgCl2 at 1.5 mM to maintain 
the osmotic pressure. 
We used the tetrazolium dye MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazomiu
m bromide) to determinate cellular viability. We 
added 10 μL of MTT (5 mg/mL) to the adherent cells 
(100 μL of medium after 2 washes with PBS) and 
incubated for 1 h at 37 °C, then added 100 μL of 0.05 
M HCl in isopropanol to dissolve the crystals and 
quantified absorption at 550 nm using a 
spectrophotometer. 
In all experiments, we calculated the basal cell 
death in the absence and presence of the different 
mAbs. These values were subtracted from those 
obtained after NK cell or NK cell+mAb treatments to 
generate the specific natural cytotoxicity or specific 
ADCC, respectively. All mAbs gave very low levels 
(<3%) of cytotoxicity in presence of heat-inactivated 
serum media. 
Evaluation of RTX-armed e-NK 
e-NK cells (2×105) were incubated for 1 h with 10 
µg/mL RTX, washed and incubated with 1:800 
solution of a goat F(ab')2 anti-human IgG (H+L) for 30 
min at 4 °C. After incubation, NK cells were washed 
with PBS and RTX binding was analyzed by FACs. As 
a control, cells were only stained with the goat F(ab')2 
anti-human IgG. 
NK degranulation assay 
Briefly, 50×103 target cells per well were placed 
in RPMI, 10% FBS, IL-2 100 U/mL with monensin (BD 
Biosciences) in a 96-well V-bottom plate. NK and 
target cells were incubated overnight at 37°C in 5% 
CO2 and living cells were counted using a Muse 
cytometer (Millipore) with the count and viability kit 
(Millipore). As a control, NK cells were incubated 
without targets. CD107a+ NK cells were analyzed on a 
Gallios flow cytometer (Beckman Coulter) using 
7AAD, CD45RO-FITC, CD19-PE, CD56-PECy7, 
CD3-APC, CD45RA-APCAlexaFluor750, CD16-Kro-
meOrange and CD107a-HV500 (BD Biosciences). 
Results were analyzed using Kaluza software. 
In vivo experiments 
In vivo experiments were carried out using 
6−8-week-old male NOD scid gamma (NSG) mice. 
Mice were bred and housed in pathogen-free 
conditions in the animal facility of the European 
Institute of Oncology–Italian Foundation for Cancer 
Research (FIRC), Institute of Molecular Oncology 
(Milan, Italy). For engraftment of human cells, mice 
were subcutaneously engrafted with 5×106 BCL-P2 or 
10×106 LNH1 primary tumor cells derived from a 
B-cell lymphoma (BCL) patient (BCL P2) or a diffuse 
large B-cell lymphoma (DLBCL) patient (LNH1). At 
day 4, we engrafted 15 (BCL-P2) or 10 (LNH1) million 
e-NK cells and at day 6, mice were treated i.p. with 
RTX (in saline medium) 3 mg/kg once a week for 3 
weeks; or with a combination of both treatments e-NK 
and RTX. Tumor growth was monitored at least once 
a week using a digital caliper, and tumor volume was 
calculated according to the formula: L × W2/2 (mm3), 
where W represents the width and L the length of the 
tumor mass. 
Statistical analysis 
Experimental figures and statistical analysis 
were performed using GraphPad Prism (v6.0). All 
statistical values are presented as * p<0.05; ** p<0.01; 
*** p<0.001 and **** p<0.0001. Mean values are 
expressed as mean plus or minus the standard error of 
the mean (SEM). 
Results 
Costimulation with the EBV lymphoblastoid 
PLH cell line more efficiently expands UCB 
NK cells for clinical use than IL-2 stimulation  
Cytokines and encounter with target cells induce 
dissimilar gene expression on NK cells [24]. We used 
umbilical cord blood (UCB) cells and compared two 
NK cell activation/expansion protocols: one using a 
high dose of the cytokine IL-2 (1000 U/mL) and the 
other using cell costimulation. The costimulation 
protocol was performed with the EBV cell line PLH 
together with low concentrations of IL-2 (100 U/mL) 
and IL-15 (5 ng/mL) [9]. NK cell expansion is 
jeopardized by T cells, therefore we depleted them 
from UCB before expansion. NK cell cultures 
underwent massive cell death at day 12 in IL-2-driven 
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expansion (data not shown). So, we compared 
different parameters that reflect NK activity at day 10: 
Proliferation. Costimulation-driven expansion 
was considerably more efficient (Figure 1A). 
Cytotoxicity. IL-2-driven expansion led to NK 
cells with superior natural cytotoxicity against K562 
(Figure 1B), Daudi (Figure S1A) and primary CD20+ 
B cell lymphoma cells (BCL P2; Figure 1C). Moreover, 
these NK cells also showed higher ADCC activity 
with RTX (Figure 1C and Figure S1A). However, 
natural cytotoxicity gradually increased in the 
costimulation protocol when cells were activated for 
longer periods of time (Figure 1D). This correlated 
with a notable large-scale expansion of cells (median ± 
SD, IL-2 10 d (16.8 ± 22.2), costimulation 10 d (140.5 ± 
235.8) and costimulation 20 d (260.9 ± 141.2), n=10). 
Activation markers. Both protocols increased the 
expression of the activation marker CD69 (Figure 
S2B) and decreased CD45RA expression to that of 
CD45RAdim cells (Figure 2B). This was associated with 
an increase in the activation marker CD45RO, as 
previously published [10]. Costimulation maintained 
higher CD16 expression (Figure S2B). 
Exhaustion markers. We investigated the 
expression of two markers that could suppress NK 
cell-mediated cytotoxicity: TIM-3 [30] and PD-1 [31]. 
While both protocols did not affect their expression, 
the mean fluorescence intensity (MFI) of positive 
populations tended to increase (Figure S2B). This 
probably reflects that, after long activation, some NK 
cells become exhausted. 
Maturation and homing markers. UCB NK cells 
showed a low percentage of CD62L+ cells (18.1% ± 
6.7%, n=3) that increased 10 d after IL-2 treatment 
(68.2% ± 13.5%) and costimulation (56.7% ± 11.9%). 
However, at day 20 post-costimulation, CD62L 
expression was lost (1.6% ± 0.4). IL-2-stimulated cells 
did not survive this long; so, we could not measure 
CD62L levels. CD62L is a "homing receptor" 
facilitating naive lymphocytes to enter secondary 
lymphoid tissues. Mature NK cells express low 
CD62L, which favors their peripheral trafficking [32]. 
In agreement with others [33], few naïve UCB 
NK cells expressed CD57 (1.2% ± 1.3%, n=3). IL-2 
stimulation barely increased expression (7.3% ± 3.9%) 
and costimulation did not change it (0.6% ± 0.6). 
Longer costimulation, i.e., 20 days, also had no effect 
(1.6% ± 0.5%). The lack of CD57 expression did not 
impair NK cell cytolytic activity (see below). 
In summary, costimulation led to higher 
numbers of activated and functional NK cells with 
higher CD16 expression. This prompted us to only use 
costimulation for the next experiments. On the other 
hand, IL-2 induced higher and faster cytotoxicity and 
could be the best option for autologous NK cell grafts. 
Frozen/thawed NK cells keep their cytolytic 
activity 
For clinical purposes, it would be advantageous 
to have a bank of cryopreserved expanded NK cells 
ready to use [34]. Compared with fresh expanded NK 
cells, frozen/thawed NK cells lost roughly 35% of 
CD16 expression and 50% of their cytolytic activity 
(Figure 1E). As shown in Figure 1D, 20 day-activation 
showed higher cytolytic activity than shorter 
expansions. For the next experiments, we used 20-21 
days costimulation-induced expansion of 
UCB-derived NK cells containing more than 90% of 
NK cells that were kept frozen until use. Hereafter, we 
call them e-NK. 
e-NK cells mediate ADCC against target cells 
with diverse CD20 levels 
We observed that e-NK performed ADCC 
similarly on Raji and Daudi cells, which express high 
CD20 levels (Figure S2A), as on primary tumor cells, 
which express low levels (Figure S2B). Even though 
P2 cells probably express more CD20 than P148, they 
were slightly less sensitive to RTX-mediated ADCC. 
In fact, e-NK performed ADCC even if their natural 
cytotoxicity against some patient cells was low or 
absent (Figure 2A and Figure S2B-E). Hence, e-NK 
show strong ADCC with RTX independently of their 
natural cytotoxicity and with lower variability (Figure 
2A-B). The glycoengineered mAb OBZ [4, 35] induced 
higher ADCC than RTX (Figure 2C and Figure 
S2B-C). 
e-NK cells can be “armed” with mAbs to 
facilitate treatment 
We next used e-NK cells coated with anti-CD20 
mAb (“armed” e-NK cells) as an alternative to 
antibody-coated target cells. “CD20-armed” e-NK 
showed similar results to opsonizing tumor cells with 
anti-CD20 (Figure S3A). The presence of RTX after 
e-NK “arming” was visualized by using a fluorescent 
anti-IgG (Figure S3B). “OBZ-armed” e-NK also 
efficiently generated ADCC (Figure S4).  
Statistical analysis of several e-NK productions 
on cells from 5 CLL patients did not show any 
differences between opsonizing targets or “arming” 
e-NK (Figure 3A). Moreover, the analysis of these 4 
e-NK expansions on the CLL targets showed that all 
productions could be armed (Figure 3B). Combining 
all these results statistically showed that significant 
ADCC was mediated by e-NK (Figure 3C). 
Cytotoxicity requires degranulation and cell 
interaction by ICAM 
Primary human NK cell cytotoxicity is largely 
independent of degranulation [36] and resides in 
 Theranostics 2018, Vol. 8, Issue 14 
 
 
http://www.thno.org 
3861 
death receptor binding on tumor cells by ligands 
expressed by NK cells. In agreement with this, e-NK 
natural cytotoxicity was only partially diminished by 
the degranulation inhibitor EGTA (Figure 4A), which 
in contrast, largely blocked ADCC. 
 
 
Figure 1. Optimization of NK cell expansion protocol. (A) Comparison of costimulation (PLH accessory cells + IL-2 100 U/mL + IL-15 5 ng/mL) and IL-2 (1000 U/mL) 
expansion protocols using three UCB donors (2903, 3464, 2928). (B) K562 cells were incubated overnight with costimulation- (circles) or IL-2-activated (triangles) NK cells from 
two different donors at different effector: target (E:T) ratios. Cell death was analyzed by 7-AAD staining. (C) BCL Patient 2 cells were incubated overnight with costimulation- 
or IL-2-activated NK cells from three different donors, in the presence (black symbols) or absence (white symbols) of RTX (10 µg/mL). (D) NK cells from 2 donors were 
expanded by costimulation for different days. At these days, NK cells were frozen. They were thawed at the same time and tested for cytotoxicity against the cell lines. (E) NK 
cells from 2 donors were expanded for 20 days and frozen or kept fresh before testing their cytotoxicity. 
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Figure 2. e-NK mediate ADCC with anti-CD20 mAbs. (A) PBMCs from CLL patient 148 were incubated for 1 h with 10 µg/mL of RTX and overnight with e-NK cells 
obtained from nine different donors at a 1:1 E:T ratio. Cell death was analyzed by 7AAD staining. The right panel shows the statistical analysis. (B) 7 e-NKs were tested against 
13 CD20+ target samples at different E:T ratios as described in (A). (C) 5 e-NKs were tested against 6 CD20+ target samples at different 1:1 E:T ratios as described in (A). 
Graphics represent mean ± SEM. Significance was determined by paired t-test; * p ≤ 0.05, ** p ≤ 0.01 and *** p ≤ 0.001. 
 
The interaction of NK cell-expressed LFA-1 with 
its target cell ligand ICAM modulates NK cell 
cytotoxicity [37]. Blocking this interaction with the 
D1D2 peptide [27] partly reduced natural cytotoxicity 
and almost completely abolished ADCC (Figure 4B). 
Therefore, our e-NK use similar mechanisms for 
eliminating target cells as primary human cells. 
e-NK mediate ADCC with daratumumab 
Next we tested if e-NK produced ADCC with the 
anti-CD38 daratumumab [38]. We used 3 target cells 
that express CD38 (MM.1S, MV4-11 and BCL-P2; 
Figure S5A) and observed that three different e-NK 
preparations showed ADCC with daratumumab 
(Figure S5B-D). In contrast, daratumumab failed to 
induce ADCC against U266 that are negative for CD38 
(Figure S5A, E). Several e-NK productions efficiently 
performed ADCC with daratumumab on MM.1S and 
P2 that was statistically significant (Figure 4C). 
e-NK mediate ADCC with cetuximab 
Next, we analyzed if e-NK cells mediate ADCC 
with other mAbs used to treat solid tumors. We used 
the cell lines Calu-1 and A549. Calu-1 cells express 
more epidermal growth factor receptor (EGFR) than 
A549 (data not shown). Both lines are targets of the 
anti-EGFR cetuximab, which has been proposed for 
use with adoptively-transferred expanded allogeneic 
NK cells in clinical trials for cervical cancer [39]. In 
fact, in vitro and clinical data suggest that cetuximab 
mediates ADCC through NK cells [23, 34]. We 
observed a relatively large variation in the natural 
cytotoxicity of the different e-NK donors versus these 
target cells. The decrease in cell viability, as measured 
by MTT formation, was low (Figure S6A). However, 
the increase in cell death, measured by annexin-V / 
7-ADD staining, was higher. This showed that e-NK 
had induced the initial steps of apoptosis (annexin-V 
staining), but longer times were required to evaluate 
cell viability with MTT. Cetuximab increased early 
apoptosis and accelerated the process of cell death, 
decreasing viability. Several e-NK productions 
efficiently performed ADCC with cetuximab on 
CALU-1 and A549 that was statistically significant 
(Figure 5A). 
EGTA diminished ADCC but insignificantly 
(Figure S6B-C). This suggested that the mechanism of 
action only partly involved degranulation, indicating 
a possible participation of death ligand-induced 
apoptosis. 
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Figure 3. Anti-CD20-armed e-NK show ADCC activity. PBMCs from CLL samples were incubated for 1 h with 10 µg/mL of RTX and overnight with donor e-NK cells at 
a 3:1 E:T ratio (antibody-coated target cells condition). Alternatively, e-NK cells were incubated for 1 h with 10 µg/mL of RTX before incubating them overnight with target cells 
(antibody-armed NK cell condition). (A) The bars represent cell death of each individual CLL sample to 4/5 e-NK preparations. (B) The bars represent cell death of each 
individual e-NK preparation to 4/5 CLL samples. B-CLL cell death was analyzed by 7-AAD. Graphics represent mean ± SEM. Significance was determined by paired t-test; * p ≤ 
0.05, ** p ≤ 0.01, *** p ≤ 0.001 and **** p ≤ 0.0001. 
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Figure 4. ADCC requires degranulation and LFA-1/ICAM interaction. (A-B) Daudi cells were incubated overnight with e-NK cells from two different donors and/or 
RTX (10 µg/mL) as described in Figure 2. Cytotoxic assays were performed also in the presence of 1 mM EGTA (A) or 15 µg/mL D1D2 protein (B). Cell death was analyzed 
by 7-AAD staining. (C) e-NK produced ADCC with daratumumab. Three different e-NK cell productions were tested against the CD38+ cell line MM.1S and BCL-P2 cells that 
express CD38. Target cells were pre-incubated for 1 h with 5 µg/mL daratumumab before overnight incubation at different E:T ratios with e-NK. Cell death was analyzed by 
7-AAD staining. Graphics represent mean ± SEM. Significance was determined by paired t-test; * p ≤ 0.05, ** p ≤ 0.01 and *** p ≤ 0.001. 
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Figure 5. e- NK perform ADCC with cetuximab and trastuzumab against EGFR- and HER2-positive cell lines, respectively. (A-B) Tumor cells were incubated 
with 5 µg/mL cetuximab (A) or trastuzumab (B) for 1 h and overnight with 4 e-NK preparations at 3:1 E:T ratio. Subsequently, we measured cell viability (MTT) and cell death 
(annexin-V/PI). (C) 1×104 SK-OV-3 cells were plated and 24 h later treated with trastuzumab and cultured with 5×105 NK cells. After 6 days, medium was removed, and cells 
were fixed and stained. The right graph shows the statistical analysis comparing cells incubated with e-NK alone or with trastuzumab. Two areas of 2 different experiments were 
counted and the mean of cells/area is depicted in the graphic. Graphics represent mean ± SEM. Significance was determined by paired t-test; * p ≤ 0.05, ** p ≤ 0.01 and *** p ≤ 
0.001. 
 
e-NK mediate ADCC with trastuzumab 
We next tested the anti-HER2 mAb trastuzumab 
on SK-BR-3 cells, which express high HER2, and A549 
cells, which express low levels. Under this condition, 
e-NK performed ADCC in both cell lines by 
decreasing viability or increasing apoptosis (Figure 
S7A). Natural cytotoxicity, as well as ADCC, heavily 
depended on degranulation because EGTA largely 
decreased both (Figure S7A-B). Statistical analysis of 
several e-NK productions on SK-BR-3 and A549 
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showed that cell viability was significantly reduced 
and apoptosis tended to increase, although this was 
not statistically significant. This suggested that e-NK 
efficiently performed ADCC with trastuzumab 
(Figure 5B). However, the increase in apoptosis was 
not statistically significant. Finally, we extended this 
study to the ovarian cell line SK-OV-3 that was 
resistant to both natural cytotoxicity and ADCC 
during short treatment (data not shown). A 6-day 
treatment revealed that NK cells, mainly with 
trastuzumab, efficiently killed these cells (Figure 5C). 
e-NK mediated ADCC in vivo 
We next evaluated e-NK activity in vivo by 
engrafting primary tumor cells from a B-cell 
lymphoma (BCL) patient (P2) or from a diffuse large 
B-cell lymphoma (DLBCL) patient (LNH1) into NSG 
mice. NSG mice have a complete null mutation by 
knockout of the γ chain of the interleukin 2 receptor 
(Il2rγ), which is a common component of the cell 
surface receptors for several cytokines, including IL-2 
and IL-15. Therefore, the signaling pathways for these 
cytokines are blocked in Il2rγ knockout mice. They 
should lack functional NK cells, which require IL15 
signaling to develop. Four days later, mice were 
engrafted with e-NK and, 2 days later, treated with 
RTX; the latter decreased tumor growth (Figure 6A), 
showing that RTX possesses direct, non-effector 
functions independently of NK cell-mediated 
effects. While e-NK also decreased tumor growth 
(Figure 6A), co-treatment was more effective, 
protecting all mice from BCL cells and 4 out of 5 mice 
from DLBCL cells. 
e-NK cells showed ADCC against 
chemoresistant cells 
EBV-activated NK cells overcome anti-apoptotic 
mechanisms active in chemoresistant cells [25, 26]. 
Overexpression of BCL-XL and MCL1 are common 
features of several hematological cancers [40]. Jurkat 
 
 
Figure 6. e-NK show ADCC in vivo and overcome mechanisms of drug resistance. (A) 5 NSG mice/group were subcutaneously engrafted with 5×106 BCLP2 (left) or 
10×106 LNH1 (right) cells and treated with e-NK and/or RTX. (B) e-NK cell-induced ADCC overcome anti-apoptotic mechanisms of drug resistance. CD20+ MEC-1 cells 
overexpressing BCL-XL and MCL1 were incubated with RTX (10 µg/mL). After 1 h, e-NK cells from 3 different donors were added overnight. Cell death was analyzed by 
7AAD/annexin-V labeling. Graphics represent mean ± SEM. Significance was determined by paired t-test; * p ≤ 0.05, ** p ≤ 0.01 and *** p ≤ 0.001. 
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cells over-expressing BCL-XL are resistant to 
doxorubicin and to soluble TRAIL [41]. MCL1 over- 
expression protects them from ibrutinib cytotoxicity 
[42]. e-NK killed the CD20+ B-CLL cell line MEC-1 
overexpressing BCL-XL or MCL1, neither of which 
conferred protection against ADCC compared to wild 
type cells (Figure S8). Several e-NK productions kill 
chemoresistant cell lines to statistically significant 
levels (Figure 6B). However, BCL-XL overexpression 
significantly decreases ADCC at high E:T ratios. This 
suggests that chemoresistance could partially protect 
tumor cells from e-NK-mediated ADCC, but not from 
e-NK natural cytotoxicity. 
Discussion 
Clinical mAbs fail to improve prognosis in a 
large number of patients. This could be due to the 
impairment of NK cells observed in most cancer 
patients [3, 16, 18]. Therefore, restoring this immune 
function should improve mAb clinical benefits. We 
focused on developing a protocol to obtain NK cells in 
sufficient number and with high ADCC activity 
together with different therapeutic mAbs. From 
UCB-derived NK, we produced e-NK that only 
partially lost ADCC function after cryopreservation 
(Figure 1) and preserved ADCC in vivo (Figure 6). 
e-NK do not require relatively high Ag levels to 
perform ADCC, since they were effective with 
different cell lines expressing variable Ag levels. 
The coupling of mAbs and e-NK should 
synergize in several clinical contexts. First, e-NKs 
should bypass NK dysfunction by increasing 
mAb-induced ADCC in patients with immune 
defects. Second, the clinical activity of NK cells is 
uncertain in solid cancers [16, 18]. Probably these 
effectors scarcely recognize solid tumor targets in vivo 
and/or fail to infiltrate these tumors—e.g., NK have 
been detected in the tumor stroma but not within the 
tumor lesion in some cases [43-45]. Moreover, the 
adoptive transfer of autologous NK cells in patients as 
single therapy maintained high levels of circulating 
NK cells but did not mediate tumor regression [3, 18, 
46]. mAbs should recruit e-NK to the selected targets 
and can also facilitate target elimination by favoring 
the recognition of opsonized cells. In fact, 
haploidentical NK cells combined with anti-GD2 mAb 
therapy has shown promising antitumor activity in 
pediatric recurrent/refractory neuroblastoma [47, 48]. 
Third, e-NKs overcome anti-apoptotic mechanisms 
active in leukemic cells (Figure 6B and [25]), allowing 
elimination of tumor cells from patients with poor 
prognosis [26]. 
e-NK could also have anti-tumor activity per se. 
First, high numbers of tumor-infiltrating NK 
correlates with a better prognosis in some tumors [16]. 
Second, NK are the first lymphocytes to recover after 
HSCT including after umbilical cord blood 
transplantation (UCBT). The speed of recovery 
correlates with the prognosis [18]. In spite of these 
findings, NK cell adoptive immunotherapy has 
provided clinical benefit. Perhaps current expansion 
protocols fail to produce enough NK cells to support 
clinical success or generate cells with impaired 
activity [16]. An inconvenience of engraftment of 
allogeneic expanded NK cell is their low survival in 
vivo [49]. The persistence of ex vivo haploidentical 
IL-2-activated and -expanded NK-DLIs reaches a 
maximum of 7 days in lymphoma patients [50]. This 
leaves grafted NK cells little time to eliminate their 
targets. The advantage is that NK will be less likely to 
generate the clinical problems found with CAR-T 
cells, which produce some chronic effects related to 
their long-term persistence ([51]; http://www 
.medscape.com/viewarticle/876591). One of the main 
concerns in using allogeneic immune cells is the 
incidence of GVHD. Allogeneic NK cells infusion is 
well tolerated in cancer patients [3, 18] and the 
severity of aGVHD correlates with impaired 
reconstitution of the NK cell compartment [52]. To our 
knowledge, engraftment of NK cells has been linked 
to GVHD only when combined to HLA-matched, 
T-cell-depleted nonmyeloablative peripheral blood 
stem cell transplantation [53]. NK cells likely 
contributed to GVHD in this setting by augmenting 
underlying T-cell alloreactivity [53]. 
An interesting alternative to allogeneic NK is 
KIR/KIRL blocking antibodies that activate 
endogenous NK cells [54]. This approach has the 
inconvenience that cancer patient NK cells are 
hyporeactive [3, 16, 18], suggesting that they are too 
inefficient to totally eliminate tumors. Moreover, 
recent clinical data suggest that such antibodies 
modify the endogenous NK repertoire. This would 
make KIR-expressing NK cells, which are those with 
higher cytolytic activity, hyporeactive [55]. This raises 
concerns about the clinical use of these antibodies. 
There are other ways to activate endogenous NK cells, 
such as the use of lenalidomide (LEN) [7, 8]. 
Preliminary results from the Phase Ib/II clinical trial 
GALEN suggest that LEN could facilitate 
OBZ-mediated NK cell activation [8], as was observed 
with RTX [56]. 
In collaboration with the University Hospital of 
Montpellier, we wish to test the clinical efficiency of 
e-NK in lymphoma patients resistant to standard 
treatments, including RTX. 
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